Hospices Civils de Lyon, Immunology Laboratory, Hôpital E, Herriot, 5, place d'Arsonval, Lyon cedex 03, France.
Curr Opin Immunol. 2013 Aug;25(4):477-83. doi: 10.1016/j.coi.2013.05.006. Epub 2013 May 28.
Preliminary studies suggest that a subgroup of septic patients with severe immune alterations is at high risk of death or nosocomial infection and therefore could benefit from adjunctive immune stimulating therapies. There is thus an urgent need for robust biomarkers usable in routine conditions evaluating rapidly evolving immune status in patients. Although functional testing remains a gold standard, its standardization remains challenging. Therefore, surrogate markers such as monocyte HLA-DR expression, are being developed. Such biomarkers of immune functionality will enable a novel approach in the design of clinical trials evaluating immunostimulating therapies in sepsis at the right time and in the right patient.
初步研究表明，一组伴有严重免疫改变的脓毒症患者具有较高的死亡或医院感染风险，因此可能受益于辅助免疫刺激治疗。因此，迫切需要在常规条件下使用可靠的生物标志物来快速评估患者不断变化的免疫状态。虽然功能测试仍然是金标准，但标准化仍然具有挑战性。因此，正在开发单核细胞 HLA-DR 表达等替代标志物。这些免疫功能的生物标志物将为临床试验设计提供一种新方法，以在适当的时间和适当的患者中评估免疫刺激治疗脓毒症的效果。
